Ganesan Vaidyanathan

List of Publications by Year
in descending order

90 papers	3,762 citations	126907 33 h-index	138484 58 g-index
91 all docs	91 docs citations	91 times ranked	3435 citing authors

#	Article	IF	Citations
1	An Improved ²¹¹At-Labeled Agent for PSMA-Targeted Î±-Therapy. Journal of Nuclear Medicine, 2022, 63, 259-267.	5.0	28
2	Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers. Scientific Reports, 2022, 12, 3020.	3.3	19
3	Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. Nuclear Medicine and Biology, 2021, 92, 171-183.	0.6	17
4	Site-Specific and Residualizing Linker for ¹⁸F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment. Journal of Nuclear Medicine, 2021, 62, 1624-1630.	5.0	8
5	Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. Nuclear Medicine and Biology, 2021, 94-95, 67-80.	0.6	9
6	Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent â€" N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate. Nuclear Medicine and Biology, 2021, 100-101, 24-35.	0.6	5
7	Gold Nanostars: A Novel Platform for Developing 211At-Labeled Agents for Targeted Alpha-Particle Therapy. International Journal of Nanomedicine, 2021, Volume 16, 7297-7305.	6.7	6
8	Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative. Bioorganic and Medicinal Chemistry, 2020, 28, 115634.	3.0	11
9	Labeling Monoclonal Antibody with Î±-emitting ²¹¹At at High Activity Levels via a Tin Precursor. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 511-519.	1.0	6
10	Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab. Molecules, 2019, 24, 3907.	3.8	8
11	The Radiopharmaceutical Chemistry of the Radioisotopes of Iodine. , 2019, , 391-408.		2
12	Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[¹⁸F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios. Molecular Pharmaceutics, 2019, 16, 214-226.	4.6	21
13	Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 1939-1949.	3.0	32
14	Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. Nuclear Medicine and Biology, 2018, 56, 10-20.	0.6	59
15	An Efficient Method for Labeling Single Domain Antibody Fragments with ¹⁸F Using Tetrazine-Trans-Cyclooctene Ligation and a Renal Brush Border Enzyme-Cleavable Linker. Bioconjugate Chemistry, 2018, 29, 4090-4103.	3.6	32
16	Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nuclear Medicine and Biology, 2018, 62-63, 18-30.	0.6	20
17	d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution. Molecules, 2018, 23, 1223.	3.8	8
18	Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. Molecular Imaging and Biology, 2017, 19, 867-877.	2.6	54

#	Article	IF	Citations
19	Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine. Current Radiopharmaceuticals, 2017, 10, 41-50.	0.8	6
20	(2S)-2-(3-(1-Carboxy-5-(4-²¹¹At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted Î±-Particle Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2016, 57, 1569-1575.	5.0	101
21	N-Succinimidyl 3-((4-(4-[¹⁸F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([¹⁸F]SFBTMGMB): a residualizing label for ¹⁸F-labeling of internalizing biomolecules. Organic and Biomolecular Chemistry, 2016, 14, 1261-1271.	2.8	25
22	Preclinical Evaluation of ¹⁸F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. Journal of Nuclear Medicine, 2016, 57, 967-973.	5.0	68
23	A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy. Theranostics, 2015, 5, 946-960.	10.0	254
24	Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. Nuclear Medicine and Biology, 2015, 42, 673-684.	0.6	21
25	D-amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. Nuclear Medicine and Biology, 2015, 42, 19-27.	0.6	9
26	Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 322-332.	6.4	50
27	Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling. Journal of Nuclear Medicine, 2014, 55, 650-656.	5.0	77
28	N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization. Nuclear Medicine and Biology, 2014, 41, 802-812.	0.6	19
29	Radiolabeling and in vitro evaluation of 67Ga-NOTA-modular nanotransporter â€“ A potential Auger electron emitting EGFR-targeted radiotherapeutic. Nuclear Medicine and Biology, 2014, 41, 441-449.	0.6	42
30	Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nuclear Medicine and Biology, 2013, 40, 52-59.	0.6	91
31	Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I. EJNMMI Research, 2012, 2, 59.	2.5	33
32	Radioiodinated O6-Benzylguanine derivatives containing an azido function. Nuclear Medicine and Biology, 2011, 38, 77-92.	0.6	11
33	An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine. Applied Radiation and Isotopes, 2011, 69, 1401-1406.	1.5	2
34	Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy. Current Radiopharmaceuticals, 2011, 4, 283-294.	0.8	62
35	[177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma. Current Radiopharmaceuticals, 2010, 3, 29-36.	0.8	7
36	Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nuclear Medicine and Biology, 2010, 37, 785-794.	0.6	91

#	Article	IF	Citations
37	Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology, 2010, 37, 741-750.	0.6	32
38	Propargyl 4-[18F]fluorobenzoate: A Putatively More Stable Prosthetic Group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry. Current Radiopharmaceuticals, 2009, 2, 63-74.	0.8	19
39	Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with 177Lu: in vitro comparison of acyclic and macrocyclic ligands. Nuclear Medicine and Biology, 2009, 36, 117-128.	0.6	28
40	Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK. Nuclear Medicine and Biology, 2009, 36, 671-680.	0.6	18
41	Targeting aldehyde dehydrogenase: a potential approach for cell labeling. Nuclear Medicine and Biology, 2009, 36, 919-929.	0.6	10
42	Engineered Modular Recombinant Transporters: Application of New Platform for Targeted Radiotherapeutic Agents to Î±-Particle Emitting 211At. International Journal of Radiation Oncology Biology Physics, 2008, 72, 193-200.	0.8	53
43	Astatine Radiopharmaceuticals: Prospects and Problems. Current Radiopharmaceuticals, 2008, 1, 177-196.	0.8	64
44	Targeted Î±-particle radiotherapy with 211At-labeled monoclonal antibodies. Nuclear Medicine and Biology, 2007, 34, 779-785.	0.6	113
45	A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [211At]MABG. Journal of Labelled Compounds and Radiopharmaceuticals, 2007, 50, 177-182.	1.0	18
46	A kit method for the high level synthesis of [211At]MABG. Bioorganic and Medicinal Chemistry, 2007, 15, 3430-3436.	3.0	56
47	Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides. Nature Protocols, 2007, 2, 282-286.	12.0	40
48	A Radioiodinated MIBGâ€“Octreotate Conjugate Exhibiting Enhanced Uptake and Retention in SSTR2-Expressing Tumor Cells. Bioconjugate Chemistry, 2007, 18, 2122-2130.	3.6	10
49	NÎµ-(3-[*I]Iodobenzoyl)-Lys5-NÎ±-maleimido-Gly1-GEEEK ([*I]IB-Mal-d-GEEEK):Â A Radioiodinated Prosthetic Group Containing Negatively Chargedd-Glutamates for Labeling Internalizing Monoclonal Antibodies. Bioconjugate Chemistry, 2006, 17, 1085-1092.	3.6	25
50	Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nuclear Medicine and Biology, 2006, 33, 101-110.	0.6	16
51	Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. Nuclear Medicine and Biology, 2006, 33, 399-407.	0.6	2
52	Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nature Protocols, 2006, 1, 1655-1661.	12.0	122
53	Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins. Nature Protocols, 2006, 1, 707-713.	12.0	55
54	O6-3-[125I]iodobenzyl-2â€²-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT). Bioorganic and Medicinal Chemistry, 2005, 13, 3889-3898.	3.0	3

#	Article	IF	Citations
55	A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1362-70.	6.4	13
56	An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. Journal of Gene Medicine, 2004, 6, 937-947.	2.8	57
57	Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. Bioorganic and Medicinal Chemistry, 2004, 12, 1649-1656.	3.0	11
58	O6-3-[131I]iodobenzylguanine:â€‰ Improved Synthesis and Further Evaluation of a Potential Agent for Imaging of Alkylguanine-DNA Alkyltransferase. Bioconjugate Chemistry, 2004, 15, 402-408.	3.6	7
59	Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides, 2004, 25, 2087-2097.	2.4	32
60	Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131i]iodo-4-phosphonomethylbenzoate ([131i]SIPMB), a negatively charged substituent bearing acylation agent. Nuclear Medicine and Biology, 2004, 31, 909-919.	0.6	19
61	Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. Nuclear Medicine Communications, 2004, 25, 947-955.	1.1	4
62	N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with Î±-particle emitting 211At. Nuclear Medicine and Biology, 2003, 30, 351-359.	0.6	48
63	N-Succinimidyl 3-[131I]Iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a Negatively Charged Substituent-Bearing Acylation Agent for the Radioiodination of Peptides and mAbs. Bioconjugate Chemistry, 2003, 14, 331-341.	3.6	29
64	Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clinical Cancer Research, 2003, 9, 1868-76.	7.0	18
65	Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nuclear Medicine and Biology, 2002, 29, 1-11.	0.6	37
66	A Polar Substituent-Containing Acylation Agent for the Radioiodination of Internalizing Monoclonal Antibodies:â€‰ N-Succinimidyl 4-Guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). Bioconjugate Chemistry, 2001, 12, 428-438.	3.6	55
67	Biological Evaluation of Ring- and Side-Chain-Substituted m-Iodobenzylguanidine Analogues. Bioconjugate Chemistry, 2001, 12, 798-806.	3.6	15
68	Synthesis of Ring- and Side-Chain-Substituted m-Iodobenzylguanidine Analogues. Bioconjugate Chemistry, 2001, 12, 786-797.	3.6	19
69	Radioiodination and astatination of octreotide by conjugation labeling. Nuclear Medicine and Biology, 2000, 27, 329-337.	0.6	28
70	Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy. Current Pharmaceutical Design, 2000, 6, 1433-1455.	1.9	174
71	Radiolabeled Guanine Derivatives for the in Vivo Mapping of O6-Alkylguanine-DNA Alkyltransferase:â€‰ 6-(4-[18F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[131I]Iodo-benzyloxy)-9H-purin-2-ylamine. Bioconjugate Chemistry, 2000, 11, 868-875.	3.6	19
72	Iodopyridine-for-Iodobenzene Substitution for Use with Low Molecular Weight Radiopharmaceuticals:Â Application tom-Iodobenzylguanidine. Bioconjugate Chemistry, 1998, 9, 758-764.	3.6	6

#	Article	IF	Citations
73	Preparation of 5-[131I]Iodo- and 5-[211At]Astato-1- (2-Deoxy-2-Fluoro-Î²-d-Arabinofuranosyl)Uracil by a Halodestannylation Reaction. Nuclear Medicine and Biology, 1998, 25, 487-496.	0.6	38
74	Method for Radioiodination of Proteins UsingN-Succinimidyl 3-Hydroxy-4-iodobenzoate. Bioconjugate Chemistry, 1997, 8, 724-729.	3.6	9
75	A New Route to Guanidines from Bromoalkanes. Journal of Organic Chemistry, 1997, 62, 4867-4869.	3.2	35
76	Fluorine-18-labeled [Nle4,d-Phe7]-Î±-MSH, an Î±-melanocyte stimulating hormone analogue. Nuclear Medicine and Biology, 1997, 24, 171-178.	0.6	58
77	Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nuclear Medicine and Biology, 1996, 23, 851-856.	0.6	32
78	No-Carrier-Added (4-Fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]Astato-4-fluorobenzyl)guanidine. Bioconjugate Chemistry, 1996, 7, 102-107.	3.6	14
79	Meta-[131I]iodobenzylguanidine uptake andmeta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. Journal of Neuro-Oncology, 1995, 25, 9-17.	2.9	16
80	No-carrier-added meta-[123I]iodobenzylguanidine: Synthesis and preliminary evaluation. Nuclear Medicine and Biology, 1995, 22, 61-64.	0.6	26
81	Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nuclear Medicine and Biology, 1995, 22, 1-12.	0.6	64
82	Fluorine-18 labeled chemotactic peptides: A potential approach for the PET imaging of bacterial infection. Nuclear Medicine and Biology, 1995, 22, 759-764.	0.6	30
83	(4-[18F]Fluoro-3-iodobenzyl)guanidine, a Potential MIBG Analog for Positron Emission Tomography. Journal of Medicinal Chemistry, 1994, 37, 3655-3662.	6.4	52
84	Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(abâ€²)2 fragment in normal dogs. Nuclear Medicine and Biology, 1994, 21, 911-919.	0.6	16
85	Improved Synthesis of N-Succinimidyl 4-[18F]Fluorobenzoate and Its Application to the Labeling of a Monoclonal Antibody Fragment. Bioconjugate Chemistry, 1994, 5, 352-356.	3.6	85
86	No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. Applied Radiation and Isotopes, 1993, 44, 621-628.	1.5	83
87	Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. Bioconjugate Chemistry, 1993, 4, 78-84.	3.6	22
88	Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1992, 19, 275-281.	0.3	73
89	1-(meta-[211At]Astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjugate Chemistry, 1992, 3, 499-503.	3.6	469
90	Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents. Bioconjugate Chemistry, 1990, 1, 269-273.	3.6	51